Literature DB >> 8983439

[Pulmonary embolism in malignancy of the lung: a retrospective clinical evaluation and pathomorphologic personal material].

B Vertun-Baranowska1, A Fijałkowska, W Tomkowski, S Filipecki, D Szymańska.   

Abstract

The incidence and clinical significance of pulmonary embolism (PE) in pulmonary malignancy were analysed among 111 autopsy cases including: 65 primary and 24 metastatic lung cancer, 8 hematological malignancies and 14-malignant pleural mesothelioma. In 34 (31%) cases PE was found, in 4 (12%) patients cancer tissue emboli was documented. In nonsmall cell lung cancer the frequency of PE was 40%, compared to 24% in small cell, 25% in metastatic lung cancer and 14% in mesothelioma. Deep venous thrombosis of lower extremities was the source of thrombotic material in 35% cases. In remaining cases the sources of thrombotic material were different (caval vein inferior, superior, and their main branches, right heart cavities, pulmonary artery). In 8 patients with PE the acute form of DIC was observed. In 15 (44%) patients the clinical ante mortem diagnosis of PE was done. In 26% of all analysed cases PE was the direct cause of death. We concluded that PE is a frequent and dangerous complication of lung neoplasms. Clinical diagnosis can be extremely difficult.

Entities:  

Mesh:

Year:  1996        PMID: 8983439

Source DB:  PubMed          Journal:  Pneumonol Alergol Pol        ISSN: 0867-7077


  3 in total

Review 1.  Primary pericardial mesothelioma unique case and literature review.

Authors:  Muhammad Rizwan Sardar; Catherine Kuntz; Toralben Patel; Wajeeha Saeed; Eric Gnall; Shotaro Imaizumi; Leah Lande
Journal:  Tex Heart Inst J       Date:  2012

2.  Pleural mesothelioma and venous thrombosis: the eosinophilia link.

Authors:  Paul Richard Julian Ames; Win Win Aye
Journal:  Thromb J       Date:  2008-04-28

3.  Limb necrosis in a lung cancer case presenting with widespread thrombosis.

Authors:  Eda Erdis; Oguz Karahan
Journal:  Case Rep Vasc Med       Date:  2012-11-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.